Business
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myelomaData further support potential of TPST-2003 to improve outcomes for patients with extramedullary disease BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will pres
About this update from Tempest Therapeutics, Inc.
[{"type":"image","alt":"Tempest Therapeutics","displaySize":"","headline":null,"caption":"Tempest Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":276,"url":"https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uJMh.dHEU6FeCJQqq.f7bQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4Ng--/https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18","width":300,"height":276}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myeloma","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Data further support potential of TPST-2003 to improve outcomes for patients with extramedullary disease","length":104,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":383,"olType":false},{"type":"text","content":"BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, May 6-9, 2026. Updates will include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest’s other dual-targeting CAR-T pipeline programs.","length":558,"tagName":"p"},{"type":"text","content":"Earlier this year, Tempest announced positive interim data from REDEEM-1, including a 100% complete response rate among all six efficacy then-evaluable patients according to the International Myeloma Working Group (IMWG) uniform response criteria, as well as a favorable safety profile.","length":291,"tagName":"p"},{"type":"text","content":"“We look forward to sharing the latest results from REDEEM-1 and updates on our other dual-targeting CAR-T programs at ISCT,” said Dr. Matt Angel, President and Chief Executive Officer of Tempest. “We believe that t...